Ifeanyichukwu Ifechidere: Cancer, Clotting and Bleeding – The Critical Role of Haemostasis in Oncology
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals, shared a post on LinkedIn:
“Cancer, clotting and bleeding: why does coagulation matter so much in oncology?
When we think about cancer, we often think about tumour biology, chemotherapy, radiotherapy and treatment response.
But there is another important piece of the puzzle that can be easy to overlook:
Haemostasis.
Cancer can significantly increase a patient’s risk of venous thromboembolism (VTE), while at the same time, the disease and its treatment can increase the risk of bleeding.
So in oncology, understanding coagulation isn’t just about interpreting a PT or APTT.
It’s about understanding the delicate balance between:
- Thrombosis and
- Bleeding
- Why are cancer patients at increased risk of thrombosis?
Malignancy can promote a prothrombotic state through multiple mechanisms, including activation of coagulation, inflammation and interactions between tumour cells and the haemostatic system.
The risk can be further influenced by:
- Type and stage of cancer
- Surgery
- Immobility
- Central venous catheters
- Certain systemic anticancer therapies
- Previous VTE
- Patient-specific risk factors
This is why VTE risk assessment is an important part of oncology care.
Where does coagulation knowledge become clinically useful?
1) VTE prophylaxis
Not every patient with cancer has the same thrombotic risk or requires the same approach.
Understanding risk helps clinicians make appropriate decisions about thromboprophylaxis while considering bleeding risk.
2) Treatment of VTE
When a patient with cancer develops DVT or pulmonary embolism, anticoagulation may be required.
But the decision isn’t simply:
‘Clot equals giving an anticoagulant.’
The patient’s bleeding risk, cancer type, treatment, renal function, platelet count and clinical circumstances all matter.
3) Chemotherapy-related bleeding
Cancer treatment can affect haemostasis in different ways.
For example, treatment-associated thrombocytopenia can significantly increase bleeding risk.
This is where laboratory monitoring becomes particularly valuable.
A platelet count, PT, APTT, fibrinogen and other haemostatic investigations can provide important pieces of the clinical picture-but they must always be interpreted in context.
The bigger lesson?
In oncology, thrombosis and bleeding are not separate problems.
They can exist in the same patient, sometimes at the same time.
That makes haemostasis a fascinating—and incredibly important-part of cancer care.
For biomedical scientists, laboratory professionals and clinicians, understanding the principles of coagulation helps us appreciate why the results matter, what questions they can answer, and when further investigation may be needed.
And behind every coagulation result is a patient whose treatment may depend on getting that balance right.
Want to build your knowledge of haemostasis, coagulation and practical laboratory medicine?
Follow me for more educational content breaking down coagulation concepts and making haemostasis easier to understand—one topic at a time.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support